Cytovance Biologics announces Regulatory Strategies for Gene Therapy Product Development webinar
08 févr. 2021 03h00 HE
|
Cytovance Biologics
OKLAHOMA CITY, Okla., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian, microbial and gene...
Cytovance Biologics Announces Bin Zhang as Chief Executive Officer
09 nov. 2020 03h00 HE
|
Cytovance Biologics
OKLAHOMA CITY, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian and microbial biologics,...
Cytovance Biologics Announces an Investment in Mass Spectrometry Services
15 juil. 2020 03h00 HE
|
Cytovance Biologics
OKLAHOMA CITY, July 15, 2020 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO), announces the addition of Mass...
Cytovance Biologics Promotes John Mott to Vice President of Development
13 juil. 2020 03h00 HE
|
Cytovance Biologics
OKLAHOMA CITY, July 13, 2020 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO), announces the promotion of Dr. John...
Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability
18 juin 2020 06h30 HE
|
Emergent BioSolutions
Company acquires property adjacent to its Canton, Massachusetts live viral drug substance development and manufacturing facility to increase campus footprint and build out advanced therapy...
Emergent BioSolutions Joins U.S. Government’s Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing
01 juin 2020 06h30 HE
|
Emergent BioSolutions
Emergent and HHS expand 2012 CIADM public-private partnership with task order valued at approximately $628 million for rapid domestic production of leading COVID-19 vaccine candidates through 2021...
Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19
23 avr. 2020 18h51 HE
|
Emergent BioSolutions
Emergent will provide contract development and manufacturing services to support Johnson & Johnson’s commitment of one billion doses of vaccine for worldwide emergency pandemic useAgreement valued...
Cytovance Biologics Promotes Dr. Jesse McCool to Chief Executive Officer
30 mars 2020 03h00 HE
|
Cytovance Biologics
OKLAHOMA CITY, March 30, 2020 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO), announces the appointment of Dr. Jesse...
Contract Development and Manufacturing Organization Market worth USD 278.98 Billion by 2026; Increasing Demand for Pharmaceutical Products Will Aid Growth, says Fortune Business Insights™
24 mars 2020 04h08 HE
|
Fortune Business Insights
Pune, March 24, 2020 (GLOBE NEWSWIRE) -- The global contract development and manufacturing organization market size is projected to reach USD 278.98 billion by the end of 2026. Mergers and...
EMERGENT BIOSOLUTIONS SIGNS DEVELOPMENT AND MANUFACTURING AGREEMENT WITH VAXART FOR THEIR EXPERIMENTAL ORAL VACCINE CANDIDATE FOR CORONAVIRUS DISEASE
18 mars 2020 06h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., March 18, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage...